Integrin-linked kinase: Both Jekyll and Hyde in rhabdomyosarcoma

Paul C. McDonald, Shoukat Dedhar, Charles Keller

Research output: Contribution to journalComment/debatepeer-review

5 Scopus citations


Although the molecular differences between embryonal rhabdomyosarcoma (ERMS) and alveolar rhabdomyosarcoma (ARMS) have been extensively interrogated, effective therapies tailored to a particular rhabdomyosarcoma subtype have yet to emerge. Patients with ERMS have shown incremental improvement using current multimodal therapy, but survival rates for metastatic ARMS remain poor. In this issue of the JCI, Durbin and colleagues demonstrate that integrin-linked kinase (ILK) acts as a tumor suppressor in ERMS and as a proto-oncogene in ARMS, and that the opposing functions of this enzyme are dependent on the JNK1 signaling pathway (see the related article beginning on page 1558). Their findings suggest that targeting ILK may represent a focused therapeutic strategy for the treatment of ARMS.

Original languageEnglish (US)
Pages (from-to)1452-1455
Number of pages4
JournalJournal of Clinical Investigation
Issue number6
StatePublished - Jun 1 2009
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Integrin-linked kinase: Both Jekyll and Hyde in rhabdomyosarcoma'. Together they form a unique fingerprint.

Cite this